Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 2 Aug 2008):
Free Full Text!
See links below

Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population.

Full Abstract

PURPOSE: To estimate the joint effects of single nucleotide polymorphisms (SNPs) in the genes complement factor H (CFH), HtrA serine peptidase 1 (HTRA1), and age-related maculopathy susceptibility 2 (LOC387715/ARMS2) in a Caucasian age related macular degeneration (AMD) case-control cohort. METHODS: We genotyped three SNPs, rs1061170 (exon 9, CFH), rs11200638 (HTRA1 promoter, -512 bp), and rs10490924 (6.6 kb upstream of HTRA1 in LOC387715/ARMS2) in 333 cases with advanced AMD (choroidal neovascularization [CNV] and geographic atrophy) and 171 age-matched examined controls. Association tests were performed for individual SNPs and jointly with the CFH SNP Y402H. Analyses for interaction were also performed. RESULTS: The linkage disequilibrium measure for two SNPs on 10q26, rs10490924 and rs11200638, is D'=0.8 and all four possible haplotypes of the two SNPs were detected in the samples. The allelic association test for rs11200638 on the promoter of HTRA1 yielded p-values less than 10(-10) for geographic atrophy, less than 10(-16) for neovascularization, and less than 10(-19) for the pooled phenotypes (with an odds ration [OR] of 3.973; 95% confidence interval [CI] 2.928, 5.390). Disease risk is conferred in a dosage-dependent fashion. Similar figures were observed for the LOC387715/ARMS2 SNP. No interaction was detected between either between the 10q26 SNPs or the CFH SNP. CONCLUSIONS: This is the first analysis to show that the two 10q26 SNPs are not in complete linkage disequilibrium. Our studies however show that both the HTRA1 and LOC387715/ARMS2 SNP appear to contribute equally to disease risk (both geographic atrophy and choroidal neovascularization) with no evidence of interaction with CFH.

 

Author information

Author/s: Francis, Peter J (PJ); Zhang, Hong (H); Dewan, Andrew (A); Hoh, Josephine (J); Klein, Michael L (ML);

Affiliation: Macular Degeneration Center, Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

Grants: R01-EY015771 (Agency:NEI NIH HHS) ; R01-EY12203 (Agency:NEI NIH HHS) ; R21-EY018127 (Agency:NEI NIH HHS)

Journal and publication information

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal: Molecular vision (Mol Vis), published in United States. (Language: eng)

Reference: 2008-; vol 14 (issue ) : pp 1395-400

Dates: Created 2008/08/06; Completed 2008/09/24; Revised 2008/11/20;

PMID: 18682806, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: ARMS2 protein, human (0) ; Proteins (0) ; Complement Factor H (80295-65-4) ; HtrA1 protein, human (EC 3.4.21.-) ; Serine Endopeptidases (EC 3.4.21.-)

Related articles

These are the most related articles currently in our database:

See 100+ related articles.

Related Article Map

6/14/2005
11/30/2008
Higher Relevance Score (60)
Lower Relevance Score (37)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.

© Advanogy LLC 2003-2010 - All rights reserved. Terms of Use | Contact Us | Index